UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 323 Estimated average burden 3235-0287 0.5 hours per response..

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)													
1. Name and Address of Reporting Person * PARSLOW JAMES F				2. Issuer Name and Ticker or Trading Symbol Xenetic Biosciences, Inc. [XBIO]						5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230			3. Date of Earliest Transaction (Month/Day/Year) 04/03/2017						X Officer (give title below) Other (specify below) Chief Financial Officer						
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
LEXINGT			(7)								_ r orm med by iv	lore than one it	eporting reison		
(City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Se (Instr. 3)	curity		2. Transaction Date (Month/Day/Year)		n D	Year)		(A (In	Securities Acquilibrium (A) or (D) (A) or (D)	of (D) Ov Tra	Amount of So wned Followi ansaction(s) str. 3 and 4)		I (Ownership of B	eneficial wnership
Reminder: R	deport on a se	eparate line for each	Table II - 1	Derivativ	e Se	ecurities A	cqui	Persons containe form dis	who responed in this formulation in this formulation in this formulation in the control when the control in the	m are no ently vali ficially O	t required t id OMB cor	o respond	unless the		74 (9-02)
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction Code		5. Number of		6. Date Exercisable and Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Employee Stock Option (Right to Buy)	\$ 4.57	04/03/2017		A		175,000		(1)	04/03/2027	Commo Stock	1175 000	\$ 0	175,000	D	
Report	ting O	wners													

	D # 0 N /411	Relationships					
Reporting Owner Name / Address		Director 10% Owne		Officer	Other		
	PARSLOW JAMES F C/O XENETIC BIOSCIENCES, INC. 99 HAYDEN AVENUE, SUITE 230 LEXINGTON, MA 02421			Chief Financial Officer			

Signatures

/s/ James F. Parslow	04/04/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares underlying the option will vest and become exercisable over three years, with one-third of the underlying shares vesting on each of April 3, 2018, April 3, 2019 and April 3, 2020, subject to the Reporting Person's continuous service with the Issuer through each such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.